Hany Elmaraghy

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials

Andrew Blauvelt, Jacob P. Thyssen, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2023 · 149 citations · Full text

Medicine, Dermatology, Pharmacology +17

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

Eric L. Simpson, Melinda Gooderham, Andreas Wollenberg et al. · JAMA Dermatology · 2023 · 143 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski et al. · British Journal of Dermatology · 2020 · 117 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial

Andrew Blauvelt, Mark Lebwohl, Tomotaka Mabuchi et al. · Journal of the American Academy of Dermatology · 2020 · 68 citations

Pharmacy, Pharmacology, Pharmacotherapy +14